Kempen: Persberichten

Persberichten 2011

Wed, 15 Feb 2012 09:38:03 +0000

Persberichten 2011 15 12 2011 Strategische samenwerkingsovereenkomst Tilburg University en Kempen Capital Management 08 12 2011Kempen & Co successfully advises Agennix AG on its €27.5 million rights issue 07 12 2011Kempen & Co to sponsor Company of

Strategische samenwerkingsovereenkomst Tilburg University en Kempen Capital Management

Thu, 15 Dec 2011 08:25:25 +0000

Kempen Capital Management en Tilburg University hebben een strategische samenwerkingsovereenkomst gesloten die tot doel heeft het wetenschappelijk onderzoek op het gebied van vermogensbeheer praktisch toepasbaar te maken.

Kempen & Co successfully advises Agennix AG on its €27.5 million rights issue

Thu, 08 Dec 2011 11:11:57 +0000

We are pleased to announce that a rights issue of € 27.5 million for German biotech company Agennix AG has been successfully completed yesterday. The subscription price was € 2.95 per share, an approximate 4% discount to the November 16, 2011 XETRA closing price of € 3.06 per Agennix share on the Frankfurt Stock Exchange, when the deal was announced.

Kempen & Co successfully advises Agennix AG on its €27.5 million rights issue

Thu, 08 Dec 2011 11:02:40 +0000

Kempen & Co to sponsor Company of the Year Award at European Mediscience Awards 2012

Wed, 07 Dec 2011 09:00:23 +0000

The European Mediscience Awards, the event which celebrates the best in the quoted life sciences, healthcare and biotech industries is delighted to announce that Netherlands-based Kempen & Co is to sponsor the prestigious Company of the Year Award at the 2012 event. Kempen & Co. joins headline sponsor, Nomura Code in confirming their association with the 11th European Mediscience Awards, which is to be held on Thursday 21 June 2012 at the Hotel InterContinental in London.